[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Kangbuk Samsung Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":197},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,46,77,103,130,151,173],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100623463","consistency-of-asis-line-vs-tuffiers-line-for-lumbar-level-identification-100623463",false,"NCT07396961","Consistency of ASIS Line vs. Tuffier's Line for Lumbar Level Identification","Evaluation of the Consistency of the ASIS Line for Lumbar Level Identification in the Lateral Decubitus Position: Comparison With the Tuffier's Line","Inclusion Criteria:\n\n* Adults aged 18 to 85 years\n* Patients scheduled for spinal anesthesia or lumbar ultrasound\n* Participants who voluntarily agreed to participate and provided written informed consent\n\nExclusion Criteria:\n\n* History of spinal surgery or spinal deformity\n* Infection or wounds at the puncture site\n* Inability to maintain the lateral decubitus position\n* Congenital lumbosacral transitional vertebrae (e.g., sacralized L5 or lumbarized S1)\n* Any other condition deemed unsuitable for the study by the investigator","ALL","18 Years","85 Years",{"count":20,"type":21},140,"ESTIMATED","OBSERVATIONAL","Tuffier's line is commonly used as a landmark for estimating lumbar vertebral levels during spinal anesthesia. However, its accuracy can vary depending on factors such as age, sex, BMI, and posture. This study evaluates the consistency of an alternative landmark, the \"ASIS line\" (a line connecting both Anterior Superior Iliac Spines), for identifying lumbar levels in the lateral decubitus position. Researchers will mark both the ASIS line and Tuffier's line on participants and use ultrasound to verify the exact vertebral level where each line crosses the spine. The goal is to determine if the ASIS line provides a more consistent and reliable estimation of lumbar levels compared to Tuffier's line.",[25,26],"Spinal Anesthesia Evaluation","Lumbar Vertebrae",[28,29,30,31,32],"vertebral level","Ultrasound","Tuffier's line","ASIS","Lateral decubitus position","NOT_YET_RECRUITING","2026-01-30",{"date":36,"type":37},"2026-02-09","ACTUAL",{"date":39,"type":21},"2026-02-20",{"date":41,"type":21},"2028-02-20",{"name":43,"class":44},"Kangbuk Samsung Hospital","OTHER",2,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},"100618800","continuous-glucose-monitoring-in-non-insulin-treated-type-2-diabetes-continuous-vs-periodic-use-100618800","NCT07336329","Continuous Glucose Monitoring in Non-Insulin Treated Type 2 Diabetes: Continuous vs. Periodic Use","Effectiveness of Periodic Use of Continuous Glucose Monitoring After Three Months of Continuous Use in Patients With Non-Insulin-Treated Type 2 Diabetes Patients: A Multicenter, Randomized, Parallel-Group, Open-Label, Non-Inferiority, Investigator-Initiated Trial","PERIODIC-CGM","Inclusion Criteria:\n\n* Adults aged 19 to 80 years at the time of informed consent\n* Adults with type 2 diabetes not using insulin\n* Patients treated with GLP-1 agonist, oral hypoglycemic agents, and\u002For lifestyle modifications\n* Patients who have maintained stable diabetes treatment for at least 3 months without changes\n* HbA1c between 7.5% and 10.0%\n* Willing to wear personal continuous glucose monitoring device (CGM)\n* Willing to install and use CGM-linked app on personal smartphone with continuous access to WIFI or cellular data\n* Able to read and write Korean as judged by investigator\n* Willing to use medically acceptable contraception until end of study (sterile status, intrauterine device, or concurrent use of male\u002Ffemale barrier method with spermicide)\n* Fully informed about the clinical trial and voluntarily consenting to participate\n\nExclusion Criteria:\n\n* Type 1 diabetes mellitus\n* Gestational diabetes mellitus\n* History of pancreatectomy\n* Continuous or intermittent insulin therapy for 7 days or more within 3 months\n* Oral or IV steroid treatment within 1 month prior to informed consent\n* Serious infection, surgery (scheduled or history), or severe trauma within 3 months prior to informed consent\n* History of malignancy within 1 year prior to informed consent (except thyroid cancer)\n* On hemodialysis or peritoneal dialysis or eGFR \\\u003C 30 mL\u002Fmin\u002F1.73m2\n* Unable to avoid the following concomitant medications, devices, or treatments during the study: CGM other than study device, X-ray\u002FMRI\u002FCT scans, radiofrequency thermal therapy, implantable devices such as pacemakers, immunosuppressants, steroids, IV vitamin preparations, cancer treatment, hemodialysis\u002Fperitoneal dialysis, insulin therapy\n* Uncontrolled thyroid disease or clinically significant severe endocrine disorders (Cushing's syndrome, pheochromocytoma, etc.)\n* Severe allergic reaction to skin adhesives (e.g., dyspnea, severe rash, edema)\n* Whole blood donation within 60 days, apheresis within 30 days, or blood transfusion within 90 days prior to device application\n* Judged by investigator as unable to handle continuous glucose monitoring device\n* Pregnant or lactating women\n* Planning pregnancy within 1 year\n* Otherwise judged by investigator as inappropriate for participation in this clinical trial","19 Years","80 Years",{"count":57,"type":21},150,"INTERVENTIONAL",[60],"NA","The goal of this clinical trial is to test whether wearing a continuous glucose monitor (CGM) part-time works as well as wearing it full-time in adults with type 2 diabetes who do not use insulin. The main questions it aims to answer are:\n\n* Does wearing CGM part-time (2 weeks per month) control blood sugar as well as wearing it continuously?\n* How do the two wearing patterns compare for blood sugar levels throughout the day, weight, blood pressure, and patient satisfaction?\n\nResearchers will compare part-time CGM use to continuous CGM use to see if part-time use is just as effective for blood sugar control.\n\nAll participants will:\n\n* Wear a CGM device continuously for 3 months to learn how their blood sugar responds to different foods and activities\n* Then be randomly assigned to wear CGM either part-time (2 weeks each month) or continuously for another 3 months\n* Replace the CGM sensor on their arm every 2 weeks\n* Use a smartphone app to track their blood sugar readings\n* Visit the clinic 3 times for blood tests and check-ups\n* Receive education on adjusting diet based on their CGM readings\n* Keep their current diabetes medications unchanged during the study\n\nThe study will last about 6 months total. Participants will use the FreeStyle Libre 2 CGM device, which is already approved for use in people with diabetes.",[63],"Diabetes Mellitus, Type 2",[65,66],"type 2 diabetes","continuous glucose monitoring","RECRUITING","2026-01-10",{"date":70,"type":37},"2026-01-13",{"date":72,"type":37},"2026-01-02",{"date":74,"type":21},"2027-06-30",{"name":43,"class":44},1,{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":84,"sex":16,"minAge":54,"maxAge":85,"enrollmentInfo":86,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":88,"conditions":89,"keywords":91,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":76},"100575538","investigations-of-factors-associated-with-treatment-response-and-prognosis-in-anxiety-disorders-100575538","NCT06773585","Investigations of Factors Associated With Treatment Response and Prognosis in Anxiety Disorders","IRPA","Inclusion Criteria\n\n1. Anxiety Behavior Group\n\n   * Adults aged 19-60 years.\n   * Diagnosed with an anxiety disorder based on DSM-5 diagnostic criteria, evaluated by a board-certified psychiatrist.\n   * Individuals who fully understand the study's purpose and process and provide informed consent.\n2. Healthy Control Group\n\n   * Adults aged 19-60 years.\n   * Individuals who report no psychiatric symptoms and are not taking any psychotropic medications.\n   * Individuals who fully understand the study's purpose and process and provide informed consent.\n\nExclusion Criteria:\n\n1. Anxiety Behavior Group\n\n   * Individuals unable to read the consent form.\n   * Individuals with difficulty using virtual reality devices.\n   * Individuals with a history of epileptic seizures, brain injuries, or neurological disorders.\n   * Individuals with severe physical illnesses (e.g., cancer, tuberculosis, severe cardiovascular diseases).\n   * Individuals with substance or alcohol use disorders.\n   * Individuals with pacemakers or implanted metallic devices.\n   * Pregnant individuals or those in vulnerable environments, such as institutional employees.\n2. Healthy Control Group\n\n   * Exclusion criteria for the Anxiety behavior group apply.\n   * Additionally, individuals with any current or past psychiatric disorders are excluded.",true,"60 Years",{"count":87,"type":21},185,"The purpose of this study is to build a comprehensive brain and behavioral dataset on anxiety disorders and identify clinical factors related to treatment response and prognosis in patients with anxiety disorders. By conducting an integrated analysis of clinical features (phenotypes), comorbid conditions, virtual reality (VR)-based behavioral data, electroencephalogram (EEG) data, and MRI-based data in patients undergoing treatment for anxiety disorders and healthy controls, this study aims to enhance the understanding of the pathophysiology of anxiety disorders and establish a foundation for precision medicine.\n\nAnxiety disorders significantly impair quality of life by inducing irrational fear and apprehension even in everyday situations. Over the past few years, the prevalence of anxiety disorders and associated medical expenses have surged, escalating the societal and economic burden. However, the current diagnostic system, DSM-5, relies on symptom-based approaches, which often lead to heterogeneity within the same diagnostic category. This limitation hinders the accurate prediction of treatment response and the design of optimal therapeutic strategies. To address these issues, the U.S. National Institute of Mental Health (NIMH) proposed the Research Domain Criteria (RDoC). RDoC is a multidimensional framework that integrates behavioral, psychological, and neurological data to facilitate the development of treatment strategies rooted in pathophysiology. Nonetheless, the acquisition of objective and reliable assessment data remains a challenge due to the inherent characteristics of mental disorders.\n\nVirtual reality (VR) technology has emerged as a promising solution to overcome these limitations. VR enables the creation of immersive 3D environments that can elicit anxiety-related behaviors and precisely evaluate them in controlled settings. It also allows data collection in scenarios that closely resemble real-life situations while offering advantages such as repeatability and ease of use. Combining behavioral data collected in VR environments with EEG data can provide a more detailed understanding of the neurophysiological representations underlying anxiety behaviors. EEG, as a biomarker reflecting neural activity in real time, facilitates intuitive and effective analyses. Moreover, MRI-based brain imaging plays a critical role in identifying structural and functional connectivity differences between anxiety disorder patients and healthy controls. It offers crucial insights into the biomarkers that predict treatment outcomes and prognosis.\n\nBy integrating these data, this study seeks to uncover the key factors influencing treatment response and prognosis in patients with anxiety disorders.",[90],"Panic Disorder",[92,93,94],"panic disorder","anxiety disorder","panic attack","2025-04-27",{"date":97,"type":37},"2025-04-30",{"date":99,"type":21},"2025-05-15",{"date":101,"type":21},"2029-12-15",{"name":43,"class":44},{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":58,"phases":113,"briefSummary":116,"conditions":117,"keywords":119,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":76},"100488493","phase-1-trastuzumab-bevacizumab-with-paclitaxel-for-her2-positive-gastric-cancer-in-a-second-line-therapy-100488493","NCT05640830","Trastuzumab, Bevacizumab with Paclitaxel for HER2-positive Gastric Cancer in a Second-line Therapy","A Phase 1B\u002F2 Study of Trastuzumab, Bevacizumab with Paclitaxel for HER2-positive Gastric Cancer in a Second-line Therapy (TREAZURE)","TREAZURE","Inclusion Criteria:\n\n1. HER2-positive advanced gastric cancer\n\n   * Defined as IHC 2+, which is IHC 3+ or SISH + (or FISH) evaluated by laboratory tests. (SISH positivity is defined as the ratio of the HER2 gene copy number to the CEP17 signal ≥ 2.0)\n   * or significant overexpression of HER2 protein on target proteomic analysis (multiple reaction monitoring)\n2. Patients who have progressed in response to one systemic anticancer therapy for advanced gastric cancer\n3. Patients who are willing and able to write a written consent form for this trial.\n4. Patients aged 19 years or older at the time of signing the subject consent form.\n5. Patients with measurable or evaluable lesions according to RECIST 1.1.\n6. ECOG activity status 0, 1 or 2\n7. as patients with adequate organ function\n\n   * Absolute neutrophil (ANC) ≥1.0 x 109\u002FL, platelet ≥100 x 109\u002FL, hemoglobin ≥9 g\u002FdL, serum creatinine ≤1.5 x ULN, total bilirubin ≤3.0 mg on laboratory tests within 2 weeks before starting treatment \u002FdL, AST\u002FALT ≤5 x ULN\n   * Echocardiogram EF ≥55% or MUGA scan ≥50%\n\nExclusion Criteria:\n\n1. Patients who have received chemotherapy, radiation therapy, immunotherapy or targeted therapy for gastric cancer within the past 2 weeks.\n2. Patients who have experienced Grade 3-4 gastrointestinal bleeding within 3 months\n3. Patients who have experienced an arteriovascular embolism event, including but not limited to myocardial infarction, transient ischemic attack, cerebrovascular disorder, or unstable angina within 6 months\n4. Ongoing or active infection, symptomatic congestive heart failure, unstable angina, symptomatic or poorly controlled cardiac arrhythmias, uncontrolled thrombotic or hemorrhagic disorders, or any other serious medical disorder not controlled in the investigator's judgment patient with\n5. Patients with a history of gastrointestinal perforation or fistula within 6 months.\n6. Concomitant diagnosis of cancer in another site or history of active malignant tumor within the past 3 years\n\n   * Excluding fully cured basal cell carcinoma and thyroid cancer, in situ cervical cancer",{"count":112,"type":21},47,[114,115],"PHASE1","PHASE2","This is a multicenter, open-label, prospective, phase 2 study of trastuzumab, bevacizumab, and paclitaxel as second-line treatment for patients with HER2-positive advanced gastric cancer who had progressed on first-line chemotherapy including trastuzumab or anti-HER2 agents.",[118],"HER2-positive Advanced Gastric Cancer",[120,121],"HER2-positive gastric cancer","trastuzumab, bevacizumab & paclitaxel","2024-11-23",{"date":124,"type":37},"2024-11-26",{"date":126,"type":37},"2023-01-01",{"date":128,"type":21},"2026-12-31",{"name":43,"class":44},{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":4,"eligibilityCriteria":136,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":137,"targetDuration":4,"studyType":58,"phases":139,"briefSummary":140,"conditions":141,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":76},"100557785","continuous-glucose-monitoring-for-glucose-and-weight-management-in-prediabetes-and-non-severe-type-2-diabetes-a-prospective-community-based-workplace-cohort-study-100557785","NCT06542627","Continuous Glucose Monitoring for Glucose and Weight Management in Prediabetes and Non-severe Type 2 Diabetes: A Prospective Community-based (Workplace) Cohort Study","Continuous Glucose Monitoring for Glucose and Weight Management in Prediabetes and Non-severe Type 2 Diabetes","Inclusion Criteria:\n\n* Subjects over the age of 19\n* Patients with type 2 diabetes\n\n  * Fasting blood glucose ≥ 126 mg\u002FdL or\n  * HbA1c ≥ 6.5% or\n  * Type 2 diabetes by clinical history and treated with antidiabetic medications or lifestyle Modifications\n* Patients with prediabetes\n\n  * Fasting blood glucose 100-125 mg\u002FdL\n  * HbA1c 5.7-6.4%\n* Willing to participate in the study\n\nExclusion Criteria:\n\n* Subjects less than 19 years old\n* Patients with type 1 diabetes\n* Pregnant at the time of screening or planning to become pregnant during the study\n* Severe chronic diseases such as cancer, stroke, proliferative retinopathy, myocardial infarction, chronic renal disease, or amputation of a diabetic foot\n* Diagnosed with or treated for myocardial infarction, stroke, end-stage renal disease, liver failure, or chronic lung disease within the past year\n* Severe liver disease (e.g., cancer, liver cirrhosis, hepatitis B, hepatitis C)\n* Diseases of the biliary tract, thyroid disorders, autoimmune disorders, or acute infections\n* Planning to be admitted to a hospital within 2 months\n* Unable to participate in the mobile intervention study as determined by the investigator",{"count":138,"type":21},420,[60],"This study aimed to evaluate the effectiveness of use of Continuous Glucose Monitoring (CGM), combined with personalized dietary education and use of smartphone applications in improving glucose control and weight management.",[142,63],"PreDiabetes","2024-08-06",{"date":145,"type":37},"2024-08-07",{"date":147,"type":37},"2023-05-22",{"date":149,"type":21},"2025-12-31",{"name":43,"class":44},{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":4,"eligibilityCriteria":157,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":158,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":160,"conditions":161,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":4},"100526084","gut-microbiome-in-people-living-with-hiv-and-hbv-100526084","NCT06130137","Gut Microbiome in People Living With HIV and HBV","Genome-based Multiomics Analysis on Gut Microbiome in People Living With HIV and HBV","Inclusion Criteria:\n\n1. HIV patients\n\n   * Inidividuals over 19 years old\n   * HIV patients on antiretroviral therapy (ART)\n2. HBV patients\n\n   * Individuals over 19 years old\n   * Chronic hepatitis B patients with either chronic hepatitis, liver cirrhosis or hepatocellular carcinoma\n\nExclusion Criteria:\n\n1. Patients with indeterminate colitis\n2. Individuals who have used antibiotics or steroids within 24 hours of the microbiome sample collection (excluding antiviral treatments for hepatitis B and HIV)\n3. Individuals who have used vaginal or external medications, including antifungal agents, within 24 hours of microbiome sample collection\n4. Those with acute illnesses, with or without fever, of moderate or severe severity; however, sampling may be postponed until the subject recovers.\n5. Individuals with gastrointestinal disorders that may impact microbiome analysis and are currently medically uncontrolled or under treatment for the respective condition\n6. Individuals with a positive result in a urine pregnancy test, pregnant, or breastfeeding at the time of microbiome sample collection\n7. Individuals for whom medical opinions suspect that they may have an impact on the sample collection at the time of microbiome collection.",{"count":159,"type":21},200,"Building a Microbiome Data Platform and Conducting Clinical Evidence Research in Individuals Infected with the Human Immunodeficiency Virus (HIV) and Hepatitis B virus.",[162,163,164],"Human Immunodeficiency Virus","Chronic Hepatitis b","Gut Microbiome","2023-11-08",{"date":167,"type":37},"2023-11-14",{"date":169,"type":21},"2023-11-27",{"date":171,"type":21},"2027-12-31",{"name":43,"class":44},{"id":174,"slug":175,"hasResults":11,"nctId":176,"briefTitle":177,"officialTitle":178,"acronym":179,"eligibilityCriteria":180,"healthyVolunteers":11,"sex":181,"minAge":4,"maxAge":4,"enrollmentInfo":182,"targetDuration":184,"studyType":22,"phases":4,"briefSummary":185,"conditions":186,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":196},"100270742","korean-borderline-ovarian-tumor-kobot-registry-100270742","NCT02803970","KOrean Borderline Ovarian Tumor (KOBOT) Registry","Establishing the Registry of Korean Patients With Borderline Ovarian Tumors","KOBOT","Inclusion Criteria:\n\n* Patients with borderline ovarian tumors (BOTs) diagnosed, treated, and followed between November 1994 and February 2015 at institutions where placed in the Republic of Korea.\n* All patients undergoing gynecologic surgery for BOTs at institutions where placed in the Republic of Korea since March, 2015\n\nExclusion Criteria:\n\n* Patients who did not receive primary treatment or follow-up for at least 6 months at each institution were excluded from analysis","FEMALE",{"count":183,"type":21},3000,"10 Years","The aim of this study is to collect data on Korean patients with borderline ovarian tumors.",[187],"Ovarian Neoplasms","2019-04-01",{"date":190,"type":37},"2019-04-03",{"date":192,"type":4},"1994-12",{"date":194,"type":21},"2040-12",{"name":43,"class":44},4,""]